Long term results of heart transplantation in patients with amyloid heart disease

被引:67
作者
Dubrey, SW
Burke, MM
Khaghani, A
Hawkins, PN
Yacoub, MH
Banner, NR [1 ]
机构
[1] Harefield Hosp, Royal Brompton & Harefield NHS Trust, Transplant Unit, Harefield UB9 6JH, Middx, England
[2] Harefield Hosp, Dept Pathol, Harefield UB9 6JH, Middx, England
[3] Royal Free Hosp, Natl Amyloidosis Ctr, London NW3 2PF, England
关键词
heart transplantation; amyloid heart disease; heart failure;
D O I
10.1136/heart.85.2.202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To determine the outcome of heart transplantation for end stage amyloid heart disease in patients treated at a single centre. Design-Records of all patients with amyloid heart disease who underwent heart transplantation were examined to determine survival, graft involvement by amyloid, the course of systemic amyloid disease, and the cause of death. Patients-10 patients, mean (SD) age 54 (8) years, received transplants in the 13 year period 1984 to 1997. Results-Two patients, both with AL amyloid (primary systemic amyloidosis), died perioperatively. Mean follow up in the remaining eight patients was 49.9 (39.5) months (range 3-116 months). Amyloid deposits in the grafts became evident histologically in five patients with AL amyloid at 5, 11, 12, 28, and 30 months after transplantation, and in one patient with familial amyloid at 60 months. Echocardiography showed no evidence of left ventricular systolic impairment at the time of recurrence. Seven patients died, at 3, 11, 26, 32, 49, 85, and 116 months after transplantation; four of these deaths were related to amyloidosis. Actuarial survival at one and two years was 60% and at five years, 30%. Conclusions-Heart transplantation for amyloid heart disease remains controversial because of the scarcity of hearts for transplantation, the systemic nature of amyloidosis, and the potential for amyloid deposition in the graft. Postoperative mortality was high (20%), reflecting extracardiac amyloid. Heart transplantation for end stage cardiac amyloidosis is feasible but, without treatment of the underlying process, it is a palliative procedure.
引用
收藏
页码:202 / 207
页数:6
相关论文
共 30 条
  • [1] HEREDITARY RENAL AMYLOIDOSIS ASSOCIATED WITH A MUTANT FIBRINOGEN ALPHA-CHAIN
    BENSON, MD
    LIEPNIEKS, J
    UEMICHI, T
    WHEELER, G
    CORREA, R
    [J]. NATURE GENETICS, 1993, 3 (03) : 252 - 255
  • [2] INHERITED AMYLOIDOSIS
    BENSON, MD
    [J]. JOURNAL OF MEDICAL GENETICS, 1991, 28 (02) : 73 - 78
  • [3] Billingham M E, 1990, J Heart Transplant, V9, P587
  • [4] Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients
    Comenzo, RL
    Vosburgh, E
    Simms, RW
    Bergethon, P
    Sarnacki, D
    Finn, K
    Dubrey, S
    Faller, DV
    Wright, DG
    Falk, RH
    Skinner, M
    [J]. BLOOD, 1996, 88 (07) : 2801 - 2806
  • [5] Comenzo RL, 1998, BLOOD, V91, P3662
  • [6] CONNER R, 1988, J HEART TRANSPLANT, V7, P165
  • [7] SELECTION AND TREATMENT OF CANDIDATES FOR HEART-TRANSPLANTATION - A STATEMENT FOR HEALTH-PROFESSIONALS FROM THE COMMITTEE ON HEART-FAILURE AND CARDIAC TRANSPLANTATION OF THE COUNCIL ON CLINICAL CARDIOLOGY, AMERICAN-HEART-ASSOCIATION
    COSTANZO, MR
    AUGUSTINE, S
    BOURGE, R
    BRISTOW, M
    OCONNELL, JB
    DRISCOLL, D
    ROSE, E
    [J]. CIRCULATION, 1995, 92 (12) : 3593 - 3612
  • [8] Criteria Committee of the New York Heart Association, 1964, Diseases of the Heart And Blood Vessels, Nomenclature and Criteria for Diagnosis, V6th, P114
  • [9] RECURRENCE OF PRIMARY (AL) AMYLOIDOSIS IN A TRANSPLANTED HEART WITH 4-YEAR SURVIVAL
    DUBREY, S
    SIMMS, RW
    SKINNER, M
    FALK, RH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (10) : 739 - &
  • [10] The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement
    Dubrey, SW
    Cha, K
    Anderson, J
    Chamarthi, B
    Reisinger, J
    Skinner, M
    Falk, RH
    [J]. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (02): : 141 - 157